|Bid||101.83 x 4000|
|Ask||101.89 x 800|
|Day's Range||101.60 - 102.24|
|52 Week Range||77.00 - 103.33|
|Beta (3Y Monthly)||0.65|
|PE Ratio (TTM)||34.82|
|Forward Dividend & Yield||0.66 (0.65%)|
|1y Target Est||N/A|
Jim Cramer sits down with Zoetis CEO Juan Ramos Alaix to discuss how parents pay for their pets' health care and a future product launch.
Zacks.com featured expert Kevin Matras highlights: Cadence Design System, CSX, Celanese and Zoetis
If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.
The best pharmaceutical stocks to buy have commonalities: Strong Composite Ratings and Relative Strength Ratings.
Zoetis Inc NYSE:ZTSView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is extremely low for ZTS with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ZTS. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding ZTS are favorable, with net inflows of $10.94 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! The latest earnings announcement Zoetis Inc. (NYSE:ZTS) released in December 2018 confirmed...
This weekend's Barron's cover story offers a head-to-head matchup of the two leading U.S. telecoms. Other featured articles examine prospects for an industrial giant undergoing a colossal restructuring ...
People are spending more on their cats and dogs, while the livestock business continues to grow. Still, opportunities are limited.
At Insider Monkey, we pore over the filings of nearly 750 top investment firms every quarter, a process we have now completed for the latest reporting period. The data we've gathered as a result gives us access to a wealth of collective knowledge based on these firms' portfolio holdings as of December 31. In this […]
CEO of Zoetis Inc (NYSE:ZTS) Juan Ramon Alaix sold 312,109 shares of ZTS on 02/28/2019 at an average price of $94.06 a share.
Pharmaceuticals are a tricky business. Public policy, science, R&D;, global growth and regulation all play a role, sometimes outsize, in the success of pharmaceutical stocks.But some Big Pharma companies and a few other industry firms have managed these and other factors better than others. And along the way, they have built up a considerable "moat" - some sort of considerable competitive advantage - around profitable businesses. Some of these same companies are building bridges to further profitability via deep drug pipelines, innovative new treatments and transformative acquisitions.Here's a deeper look into five pharmaceutical stocks that have compelling moats, bridges or both. These advantages make them more likely to provide stable growth over the long term. SEE ALSO: The Best Health-Care Stocks to Buy for 2019
This article is written for those who want to get better at using price to earnings ratios (P/E ratios). We'll look at Zoetis Inc.'s (NYSE:ZTS) P/E ratio and reflect onRead More...
Elanco or Zoetis: Which Is a Better Animal Health Pick in February?(Continued from Prior Part)Underperforming businesses In its fourth-quarter earnings conference call, Elanco Animal Health (ELAN) reported a 4% YoY drop in sales driven by a 9%
Elanco or Zoetis: Which Is a Better Animal Health Pick in February?(Continued from Prior Part)Revenue performance in fiscal 2018In fiscal 2018, Zoetis (ZTS) reported revenues of $5.83 billion, a YoY rise of 10.0% on a reported basis and 8% on an
Elanco or Zoetis: Which Is a Better Animal Health Pick in February?(Continued from Prior Part)Expense guidance for fiscal 2019In its mid-December 2018 guidance call, Elanco Animal Health (ELAN) highlighted various restructuring activities aimed at
Elanco or Zoetis: Which Is a Better Animal Health Pick in February?(Continued from Prior Part)EPS guidance for fiscal 2019In its fourth-quarter earnings investor presentation, Elanco Animal Health (ELAN) reiterated its fiscal 2019 GAAP and non-GAAP
Elanco or Zoetis: Which Is a Better Animal Health Pick in February?Stock price movementsOn February 19, Elanco Animal Health (ELAN) closed at $29.16, 1.49% lower than its previous closing price, 4.14% higher than its 52-week low of $28.00, and
In his second "Executive Decision" segment of Mad Money Friday night, Jim Cramer sat down with Juan Ramon Alaix, CEO of Zoetis Inc. ZTS is an animal health company with shares that vaulted 9.8% last week after another strong quarter. Alaix added that Zoetis has effective treatments for a number of conditions, including ticks, fleas, heartworm and other parasites.
Announcement: Moody's announces completion of a periodic review of ratings of Zoetis Inc. New York, February 15, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Zoetis Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.